Grifols, S.A.
GRFS
Positions held
Your positionsGRFS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Grifols operates in the healthcare sector, focusing on the drug manufacturing industry, which is essential for addressing global health challenges and has a growing demand for innovative therapies.
- In Q2 2026, Grifols reported a revenue of $1.874 billion, a 10% increase compared to the previous quarter.
- The company's gross margin improved to 37.6% in Q2 2026, up from 36.5% in Q1 2026.
- The company's financial health is concerning, with a strong sell signal indicating potential risks in its stock performance.
- Grifols' revenue growth has been negative at -0.9%, reflecting challenges in maintaining sales momentum.
- The trailing P/E ratio stands at 9.64, suggesting the stock may be undervalued, but the overall market sentiment remains bearish.
Fundamentals
| Market cap | $5.04B | Enterprise value | $21.34B | Trailing P/E | 9.62 | Forward P/E | 5.14 |
| PEG | 0.19 | Price / book | 1.62 | Beta | 1.20 | Dividend yield | 1.43% |
| Revenue growth | -0.9% | Earnings growth | 32.9% | Gross margin | 37.8% | Operating margin | 15.9% |
| Profit margin | 6.1% | ROE | 6.9% | ROA | 4.2% | Debt / equity | 1.17 |
| Current ratio | 2.37 | Free cash flow | $572.92M | Analyst recommendation | none | Mean target | $10.87 |
| 52w high | $9.90 | 52w low | $6.96 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|
| Revenue | $1.9B | $1.7B | $2.0B | $1.9B | $1.8B |
| Op margin | 17.6% | 14.6% | 13.9% | 18.5% | 15.3% |
| Net income | $155M | $73.0M | $98.3M | $117M | $60.0M |
| Gross margin | 37.6% | 36.5% | 34.7% | 39.3% | 38.9% |
| Gross profit | $705M | $620M | $687M | $744M | $695M |
| Operating income | $329M | $249M | $275M | $350M | $274M |
- Revenue +10% vs prior quarter ($1.9B vs $1.7B).
- Gross margin 37.6% (was 36.5% prior quarter).
- Operating margin expanded to 17.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $7.5B | $7.2B | $6.6B | $6.1B | — |
| Op margin | 16.6% | 16.0% | 10.9% | 11.2% | — |
| Net income | $402M | $157M | $42.0M | $185M | — |
| Gross margin | 38.0% | 38.7% | 37.7% | 36.5% | — |
| Gross profit | $2.9B | $2.8B | $2.5B | $2.2B | — |
| Operating income | $1.3B | $1.2B | $718M | $679M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Are Options Traders Betting on a Big Move in Grifols Stock?
2026-09-26 · Grifols (BME:GRF) Stock May Be Below Fair Value On Earnings
2026-09-25 · European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading; Down for Week
2026-09-24 · GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?
2026-09-10 · European Equities Traded in the US as American Depositary Receipts Drop in Thursday Trading
2026-09-08 · GRFS or SDZNY: Which Is the Better Value Stock Right Now?
2026-09-01 · European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading
2026-08-19 · European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
2026-08-14 · OPSEU/SEFPO: Permanently end for-profit plasma collection to protect public health
2026-08-10 · Grifols Completes Clinical Portion of Phase 3 Trial of Prolastin-C in Emphysema
2026-08-05 · European Equities Traded in the US as American Depositary Receipts Edge Up in Wednesday Trading
2026-07-31 · European Equities Traded in the US as American Depositary Receipts Decline Friday
Price (daily)
Full chart · RSI · MACD · patterns